# AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

> **NCT00719550** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 130 (actual)

## Conditions studied

- Esophagogastric Junction Adenocarcinoma
- Gastric Cancer
- Esophageal Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Epirubicin
- **DRUG:** AMG 102
- **DRUG:** Cisplatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00719550
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2010-11
- **Final completion:** 2013-06
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2013-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00719550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00719550, "AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00719550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*